MENU
PBE
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

PBE stock forecast, quote, news & analysis

The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index... Show more

Category: #Health
PBE
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for PBE with price predictions
Jul 31, 2026

PBE's RSI Oscillator leaves overbought zone

The 10-day RSI Oscillator for PBE moved out of overbought territory on July 10, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 instances where the indicator moved out of the overbought zone. In of the 23 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 62 cases where PBE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on July 31, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PBE as a result. In of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for PBE turned negative on July 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PBE advanced for three days, in of 309 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 234 cases where PBE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Illumina (NASDAQ:ILMN), Biogen (NASDAQ:BIIB), Incyte Corp (NASDAQ:INCY), Exact Sciences Corp (NASDAQ:EXAS), Exelixis (NASDAQ:EXEL), BioCryst Pharmaceuticals (NASDAQ:BCRX).

Industry description

The investment seeks to track the investment results (before fees and expenses) of the Dynamic Biotech & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Market Cap

The average market capitalization across the Invesco Biotechnology & Genome ETF ETF is 25.99B. The market cap for tickers in the group ranges from 270.12M to 207.87B. AMGN holds the highest valuation in this group at 207.87B. The lowest valued company is MYGN at 270.12M.

High and low price notable news

The average weekly price growth across all stocks in the Invesco Biotechnology & Genome ETF ETF was 0%. For the same ETF, the average monthly price growth was -0%, and the average quarterly price growth was 11%. CDNA experienced the highest price growth at 18%, while MYGN experienced the biggest fall at -49%.

Volume

The average weekly volume growth across all stocks in the Invesco Biotechnology & Genome ETF ETF was 96%. For the same stocks of the ETF, the average monthly volume growth was 48% and the average quarterly volume growth was -5%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 63
P/E Growth Rating: 47
Price Growth Rating: 41
SMR Rating: 66
Profit Risk Rating: 69
Seasonality Score: -16 (-100 ... +100)
View a ticker or compare two or three
PBE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
Powershares Exchange Traded Fund Trust227 E Prairie AveWheaton
Phone
N/A
Web
www.invescopowershares.com
PBE's RSI Oscillator leaves overbought zone